A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib

BACKGROUND: Endoglin is an endothelial cell membrane receptor essential for angiogenesis and highly expressed on the vasculature of many tumor types, including hepatocellular carcinoma (HCC). TRC105 is a chimeric IgG1 anti-CD105 monoclonal antibody that inhibits angiogenesis and tumor growth by endo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:United European Gastroenterol J
Autores principales: Duffy, AG, Ulahannan, SV, Cao, L, Rahma, OE, Makarova-Rusher, OV, Kleiner, DE, Fioravanti, S, Walker, M, Carey, S, Yu, Y, Venkatesan, AM, Turkbey, B, Choyke, P, Trepel, J, Bollen, KC, Steinberg, SM, Figg, WD, Greten, TF
Formato: Artigo
Lenguaje:Inglês
Publicado: SAGE Publications 2015
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4625750/
https://ncbi.nlm.nih.gov/pubmed/26535124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2050640615583587
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares